Galleri by GRAIL vs Oncotype DX
Side-by-side comparison of cancer screening tests.
← Back to Cancer Screening
Test Performance
| Feature | Galleri by GRAIL | Oncotype DX |
|---|---|---|
| Price | $949 | Variable |
| Cancers Detected | 50+ cancers | Breast recurrence risk |
| Sensitivity | >70% for the 12 deadliest cancers | N/A |
| Specificity | 99.6% (0.4% false positive rate) | N/A |
| Sample Type | Blood draw | Tumor tissue |
| FDA Status | Not FDA approved (PMA under review;advisory panel Sept 2026) | Guideline recommended |